MX2025009331A - Acidos nucleicos y usos de los mismos - Google Patents

Acidos nucleicos y usos de los mismos

Info

Publication number
MX2025009331A
MX2025009331A MX2025009331A MX2025009331A MX2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A MX 2025009331 A MX2025009331 A MX 2025009331A
Authority
MX
Mexico
Prior art keywords
nucleic acids
sarna
self
disclosed
methods
Prior art date
Application number
MX2025009331A
Other languages
English (en)
Inventor
Pirada Suphaphiphat Allen
Ye Che
Moreno Raquel Munoz
Quijano Alicia Solorzano
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2025009331A publication Critical patent/MX2025009331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en este documento moléculas de ARN autoamplificantes (ARNsa) que codifican un antígeno del virus de la influenza y métodos de uso de las mismas.
MX2025009331A 2023-02-09 2025-08-08 Acidos nucleicos y usos de los mismos MX2025009331A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363484186P 2023-02-09 2023-02-09
US202363484747P 2023-02-13 2023-02-13
US202463621102P 2024-01-15 2024-01-15
PCT/IB2024/051087 WO2024165992A1 (en) 2023-02-09 2024-02-06 Nucleic acids and uses thereof

Publications (1)

Publication Number Publication Date
MX2025009331A true MX2025009331A (es) 2025-09-02

Family

ID=89897995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025009331A MX2025009331A (es) 2023-02-09 2025-08-08 Acidos nucleicos y usos de los mismos

Country Status (10)

Country Link
EP (1) EP4661903A1 (es)
JP (1) JP2026514290A (es)
KR (1) KR20250140103A (es)
CN (1) CN120882425A (es)
AU (1) AU2024218431A1 (es)
CO (1) CO2025010720A2 (es)
IL (1) IL322137A (es)
MX (1) MX2025009331A (es)
PE (1) PE20252441A1 (es)
WO (1) WO2024165992A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132839A1 (en) * 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019321186B2 (en) * 2018-08-17 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof
US20240009296A1 (en) * 2022-07-10 2024-01-11 Pfizer Inc. Self-amplifying rna encoding an influenza virus antigen

Also Published As

Publication number Publication date
JP2026514290A (ja) 2026-05-08
CN120882425A (zh) 2025-10-31
PE20252441A1 (es) 2025-10-20
EP4661903A1 (en) 2025-12-17
WO2024165992A1 (en) 2024-08-15
CO2025010720A2 (es) 2025-09-08
AU2024218431A1 (en) 2025-08-14
IL322137A (en) 2025-09-01
KR20250140103A (ko) 2025-09-24

Similar Documents

Publication Publication Date Title
MX2025000397A (es) Arn autoamplificador que codifica un antigeno del virus de la gripe
BR112022025653A2 (pt) Vacina autoamplificante de rna sars-cov-2
GEAP202416053A (en) Modified short interfering nucleic acid (sina) molecules and uses thereof
WO2021173896A8 (en) Materials and methods for modulating an immune response
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
CR20240095A (es) Vacunas de arn
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
MX2022009943A (es) Vacunas intranasales de arnm.
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
PH12021552176A1 (en) Antibodies and methods for treatment of influenza a infection
WO2024191860A3 (en) Nucleic acid influenza vaccines and respiratory virus combination vaccines
SA522441314B1 (ar) لقاحات لوُرام حليمي تنفسي متكرر وطرق استخدامها
CO2025010720A2 (es) Ácidos nucleicos y usos de los mismos
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
BR112022012350A2 (pt) Nucleases de spcas9 de alta fidelidade para modificação de genoma
WO2022009052A3 (en) Prostate neoantigens and their uses
BR112021024409A2 (pt) Célula mutante nocaute de mdbk irf3/irf7 e seu uso para produção de vacina
MX2021002933A (es) Nucleasa pacas9.
MX2022004836A (es) Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso.
MX2018007260A (es) Metodos y composiciones de control de insectos.
MX2020007676A (es) Antígenos t grandes y pequeños del poliomavirus de células de merkel, construcciones de ácido nucleico y vacunas fabricadas con ellos, y métodos de usar los mismos.
WO2022169861A3 (en) Gene therapy for angelman syndrome
WO2021158982A3 (en) Targeted translation of rna with crispr-cas13 to enhance protein synthesis